Meta-Analysis of the Efficacy and Safety of Finerenone in Diabetic Kidney Disease
Kidney & Blood Pressure Research, 2022 Background: The phase III clinical trial of the nonsteroidal mineralocorticoid receptor antagonist finerenone (BAY 94-8862) has been completed, aiming to investigate renal and cardiovascular outcomes in type 2 diabetes (T2D) with chronic kidney disease ...
Yaning Zheng +6 more
doaj +1 more source
Dose–Exposure–Response Analysis of the Nonsteroidal Mineralocorticoid Receptor Antagonist Finerenone on UACR and eGFR:An Analysis from FIDELIO-DKD [PDF]
, 2022 Background and Objective: Finerenone reduces the risk of kidney failure in patients with chronic kidney disease and type 2 diabetes. Changes in the urine albumin-to-creatinine ratio (UACR) and estimated glomerular filtration rate (eGFR) are surrogates ...
Brinker, Meike +6 more
core +1 more source
Cardiovascular Diabetology, 2023 Finerenone is a novel non-steroidal mineralocorticoid receptor (MR) antagonist (MRA) with high binding affinity, high MR selectivity and a short plasma half-life.
Ulrich Kintscher, Frank Edelmann
doaj +1 more source
Finerenone: A Potential Treatment for Patients with Chronic Kidney Disease and Type 2 Diabetes Mellitus [PDF]
, 2021 Type 2 diabetes mellitus (T2DM) affects an estimated 463 million people worldwide, equivalent to 1 in 11 adults. Moreover, the rapid growth of this disease has resulted in a high incidence of diabetic kidney disease (DKD), which, together with ...
Bermúdez, Valmore +9 more
core +1 more source
Frontiers in Pharmacology, 2022 Background: Chronic kidney disease (CKD) is a global public health issue. In recent years, the effectiveness of finerenone for treatment of CKD has been the subject of considerable debate.
Ming-Zhu Zhang +9 more
doaj +1 more source
Rationale and design of a randomised phase III registration trial investigating finerenone in participants with type 1 diabetes and chronic kidney disease: The FINE-ONE trial [PDF]
, 2023 AIMS: Despite guideline-recommended treatments, including renin angiotensin system inhibition, up to 40 % of individuals with type 1 diabetes develop chronic kidney disease (CKD) putting them at risk of kidney failure.
et al., +2 more
core +5 more sources
Rationale and design of MinerAlocorticoid Receptor antagonist Tolerability Study‐Heart Failure (ARTS‐HF): a randomized study of finerenone vs. eplerenone in patients who have worsening chronic heart failure with diabetes and/or chronic kidney disease [PDF]
, 2015 Peer Reviewedhttp://deepblue.lib.umich.edu/bitstream/2027.42/110733/1/ejhf218 ...
Albert +39 more
core +2 more sources
Finerenona: completando el abordaje del paciente con enfermedad renal y diabetes [PDF]
, 2023 Chronic kidney disease; Fibrosis; InflammationEnfermedad renal crónica; Fibrosis; InflamaciónMalaltia renal crònica; Fibrosi; InflamacióDespite current treatments, which include renin angiotensin system blockers and SGLT2 inhibitors, the risk of ...
Facila Rubio, Lorenzo +5 more
core +2 more sources
The novel mineralocorticoid receptor antagonist finerenone attenuates neointima formation after vascular injury. [PDF]
PLoS ONE, 2017 The novel nonsteroidal mineralocorticoid receptor (MR) antagonist finerenone holds promise to be safe and efficient in the treatment of patients with heart failure and/or chronic kidney disease.
Jochen Dutzmann +8 more
doaj +1 more source
Terapia diuretica nell’insufficienza cardiaca cronica: evidenze, esperienze, prospettive = Diuretic treatment in patients with chronic heart failure: evidences, experiences, and current perspectives [PDF]
, 2017 Congestion is a fundamental clinical sign in patients with chronic heart failure (CHF). Diuretics are the mainstay treatment for congestion but, so far, no randomized trial has ever shown any beneficial effect of diuretics on mortality in patients with ...
Carubelli, Valentina +1 more
core +1 more source